Waypoint Capital Advisors’s Pfizer PFE Stock Holding History

Waypoint Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$260K	Buy	8,980 +468	+5%	+$13.7K	0.06%	114
2024 Q2	$238K	Buy	8,512 +759	+10%	+$20.9K	0.06%	114
2024 Q1	$215K	Buy	7,753 +407	+6%	+$11.3K	0.06%	112
2023 Q4	$211K	Sell	7,346 -425	-5%	-$12.8K	0.06%	113
2023 Q3	$258K	Sell	7,771 -186	-2%	-$6.58K	0.09%	102
2023 Q2	$292K	Buy	7,957 +186	+2%	+$7.24K	0.09%	117
2023 Q1	$317K	Hold	7,771	–	–	0.1%	112
2022 Q4	$398K	Sell	7,771 -168	-2%	-$8.05K	0.14%	96
2022 Q3	$348K	Buy	7,939 +4	+0.1%	+$194	0.15%	83
2022 Q2	$416K	Sell	7,935 -433	-5%	-$22.1K	0.19%	72
2022 Q1	$433K	Sell	8,368 -440	-5%	-$22.8K	0.25%	74
2021 Q4	$520K	Buy	+8,808	New	+$436K	0.36%	56

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Waypoint Capital Advisors's PFE Position: Q3 2024 in Review

Waypoint Capital Advisors increased its Pfizer (PFE) stake by 5.5% in Q3 2024, buying an estimated $13.7K and bringing the position to 8,980 shares worth $260K. The position accounts for 0.06% of the portfolio, ranked #114.

Waypoint Capital Advisors first reported a position in PFE in Q4 2021 and has held it in 12 quarters since. The position peaked at $520K in Q4 2021. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.

Waypoint Capital Advisors held 8,980 shares of Pfizer worth $260K as of Q3 2024.
Waypoint Capital Advisors bought 468 Pfizer shares in Q3 2024, an estimated $13.7K.
Pfizer made up 0.06% of Waypoint Capital Advisors's portfolio in Q3 2024, its #114 holding.
Waypoint Capital Advisors first reported a position in Pfizer in Q4 2021 and has held it in 12 quarters since.
Waypoint Capital Advisors's Pfizer position peaked at $520K in Q4 2021.
2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.

Based on Waypoint Capital Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.